Clarity Pharmaceuticals (ASX:CU6) Change In Working Capital : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Clarity Pharmaceuticals Change In Working Capital?

Clarity Pharmaceuticals's change in working capital for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Clarity Pharmaceuticals's change in working capital for the fiscal year that ended in Jun. 2023 was A$0.00 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Clarity Pharmaceuticals Change In Working Capital Historical Data

The historical data trend for Clarity Pharmaceuticals's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals Change In Working Capital Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

Change In Working Capital

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Working Capital	Get a 7-Day Free Trial			-	-	-	-	-

Clarity Pharmaceuticals Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Clarity Pharmaceuticals Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals (ASX:CU6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (ASX:CU6) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

CLRPF:USA

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

Clarity Pharmaceuticals (ASX:CU6) Headlines

No Headlines